ArticleJournal of medicinal chemistry2021
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Antibody‒drug conjugates with DHODH inhibitor as novel payload class for cancer and SARS-CoV-2 infection therapies.Acta pharmaceutica Sinica. B · 2026Article
- Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review.Biochemical Society transactions · 2026Review
- Fluorescent Isostere (Journal of medicinal chemistry · 2025Article
- Identification of a Non-Retinoid Opsin Ligand Through Pharmacophore-Guided Virtual Screening-A Novel Potential Rhodopsin-Stabilizing Compound.Molecules (Basel, Switzerland) · 2025Article
- Discovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors.ACS medicinal chemistry letters · 2024Article
- The NovelViruses · 2022Article
- Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-Journal of medicinal chemistry · 2022Article
- Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.Cell death & disease · 2022Article
- Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.Molecules (Basel, Switzerland) · 2022Article
- A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.Oncology research · 2022Article
- The New GenerationMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 3 countries.
Stefano SainasDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0001-5010-8536
Marta GiorgisDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-3282-1220
Paola CircostaDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0001-8251-6905
Valentina GaidanoDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0003-0701-7975
Davide BonanniDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-8832-0492
Agnese C PippioneDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-3778-8420
Renzo BagnatiDepartment of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milano 20156, Italy.ORCID 0000-0002-6535-2686
Alice PassoniDepartment of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milano 20156, Italy.ORCID 0000-0001-6003-5932
Yaqi QiuLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Strada Provinciale, 142-KM 3.95, Candiolo, Turin 10060, Italy.ORCID 0000-0002-3135-7550
Carina Florina CojocaruLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Strada Provinciale, 142-KM 3.95, Candiolo, Turin 10060, Italy.ORCID 0000-0003-2340-6559
Barbara CanepaGem Forlab srl, Via Ribes, 5, Colleretto Giacosa, Turin 10010, Italy.
Alessandro BonaGem Chimica srl, Via Maestri del Lavoro, 25, Busca, Cuneo 12022, Italy.
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0001-6138-1503
Mariia MishinaDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-2951-8789
Cristina RamondettiDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0002-0501-5696
Barbara BuccinnàDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0002-5843-7112
Marco PiccininiDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0003-2287-0704
Mohammad HoushmandDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0001-7503-6452
Alessandro CignettiDivision of Hematology and Cell Therapy, AO Ordine Mauriziano, Largo Filippo Turati, 62, Turin 10128, Italy.ORCID 0000-0003-2109-1194
Enrico GiraudoDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-4128-4786
Salam Al-KaradaghiDepartment of Biochemistry and Structural Biology, Lund University, Naturvetarvägen 14, Box 124, Lund 221 00, Sweden.ORCID 0000-0001-8608-0635
Donatella BoschiDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-4929-4460
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0002-1046-3514
Marco L LolliDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-3030-3163
University of Turin · ITCandiolo Cancer Institute · ITA. O. Ordine Mauriziano di Torino · ITMario Negri Institute for Pharmacological Research · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITIndustriale Chimica (Italy) · ITLund University · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The connection with acute myelogenous leukemia (AML) of dihydroorotate dehydrogenase (
Indexed as
AnimalsApoptosisBinding SitesBiphenyl CompoundsCell DifferentiationCell Line, TumorDihydroorotate DehydrogenaseDrug DesignEnzyme InhibitorsFemaleHalf-LifeHumansLeukemia, Myeloid, AcuteMaleMiceMice, Inbred BALB CbiphenylBiphenyl CompoundsDihydroorotate DehydrogenaseEnzyme InhibitorsOxidoreductases Acting on CH-CH Group DonorsPyrazolespyrazolo(3,4-b)pyridinePyridines
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.